Name: ONCOLYTICS BIOTECH INC (ONCY) Stock
Brand: ONCOLYTICS BIOTECH INC
Rating: 3.5 (3 reviews)

ONCY Latest News, Press Relases and Analysis

All

Press Releases

12 days ago - By: Chartmill - Mentions: VNDA COO AGX SPWH ...

Curious about the stocks that are showing activity after the closing bell on Thursday?

an hour ago - By: Equity Insider - Mentions: IMNM PRLD CNTX RLAY

Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards

5 hours ago - By: Oncolytics Biotech Inc.

Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer

4 days ago - By: Equity Insider - Mentions: AGEN EXEL CRDF GILD

GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era

7 days ago - By: Oncolytics Biotech Inc.

Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada

13 days ago - By: Zacks Investment Research

Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

26 days ago - By: Oncolytics Biotech Inc.

Oncolytics Biotech® Provides Update on Special Meeting of Shareholders

a month ago - By: Zacks Investment Research

All You Need to Know About Oncolytics Biotech (ONCY) Rating Upgrade to Buy

a month ago - By: FN Media Group LLC - Mentions: ALXO ERAS IMRX PRLD

Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

a month ago - By: Oncolytics Biotech Inc.

Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer

a month ago - By: Oncolytics Biotech® Inc.

Oncolytics Biotech® Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy

2 months ago - By: Oncolytics Biotech® Inc.

Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care

2 months ago - By: Oncolytics Biotech® Inc.

Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada

2 months ago - By: Benzinga - Mentions: IVA ARAY KIDS VNRX ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

3 months ago - By: Oncolytics Biotech® Inc.

Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study

3 months ago - By: Oncolytics Biotech® Inc.

Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion

3 months ago - By: Benzinga - Mentions: AHG COCP CHEK HSDT ...

12 Health Care Stocks Moving In Monday's Pre-Market Session

3 months ago - By: Oncolytics Biotech® Inc.

Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions

4 months ago - By: Oncolytics Biotech® Inc.

ONCOLYTICS BIOTECH INC (ONCY) Stock News

ONCY Latest News, Press Relases and Analysis

Curious about the stocks that are showing activity after the closing bell on Thursday?

Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards

Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer

GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era

Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada

Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Oncolytics Biotech® Provides Update on Special Meeting of Shareholders

All You Need to Know About Oncolytics Biotech (ONCY) Rating Upgrade to Buy

Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer

Oncolytics Biotech® Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy

Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care

Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada

12 Health Care Stocks Moving In Friday's Pre-Market Session

Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study

Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion

12 Health Care Stocks Moving In Monday's Pre-Market Session

Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions

Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors